News & PR
ReGenTree Announces Additional Results from ARISE-3 and After Pooling Data from Three Phase 3 Clinical Trials Using RGN-259 for the Treatment of Dry Eye
2021.05.14
ReGenTree Announces Additional Results from ARISE-3 and After Pooling Data from Three Phase 3 Clinical Trials Using RGN-259 for the Treatment of Dry Eye
(if you want to view the body of article, click on the bottom link)
23개(1/2Page)